

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-59)

OLUTASIDENIB

PRONUNCIATION

oh loo" ta sid' e nib


THERAPEUTIC CLAIM

Treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with mutations in the IDH1 gene

CHEMICAL NAMES

1. 2-Pyridinecarbonitrile, 5-[[[(1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl]amino]-1,6-dihydro-1-methyl-6-oxo-
2. 5-[[[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino]-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
3. (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

STRUCTURAL FORMULA



MOLECULAR FORMULA

C<sub>18</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub>

MOLECULAR WEIGHT

354.8

TRADEMARK

None as yet

SPONSOR

FORMA Therapeutics, Inc.

CODE DESIGNATIONS

FT-2102

CAS REGISTRY NUMBER

1887014-12-1

UNII

0T4IMT8S5Z

WHO NUMBER

11036

gbk